Evidence map›Paper›PMID 41008802›Full record

ArticleCancers2025

Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models.

Daniela D De Nobrega, Logan C Eiler, Parmanand Ahirwar, Sonika Nallapu, Urvi P Rawal, Chelsea L Crawford, Donald J Buchsbaum, Adam B Keeton, Yulia Y Maxuitenko, Xi Chen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Daniela D De NobregaCerFlux, Birmingham, AL 35203, USA.
Logan C EilerCerFlux, Birmingham, AL 35203, USA.
Parmanand AhirwarCerFlux, Birmingham, AL 35203, USA.ORCID 0000-0003-1910-5016
Sonika NallapuCerFlux, Birmingham, AL 35203, USA.
Urvi P RawalCerFlux, Birmingham, AL 35203, USA.
Chelsea L CrawfordCerFlux, Birmingham, AL 35203, USA.
Donald J BuchsbaumCerFlux, Birmingham, AL 35203, USA.
Adam B KeetonDrug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
Yulia Y MaxuitenkoDrug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.ORCID 0000-0001-5518-4941
Xi ChenDrug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
Gary A PiazzaDrug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.ORCID 0000-0003-4418-887X
Allan TsungDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22901, USA.
Karim I BudhwaniCerFlux, Birmingham, AL 35203, USA.ORCID 0000-0001-8823-1695

Funding

Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatmentR01CA238514 · NCI · AUGUSTA UNIVERSITY · PI PIAZZA, GARY A, ZHOU, GANG · 2020 to 2024
$2.1M
Novel inhibitor for oncogenic RAS for lung cancerR01CA254197 · NCI · AUBURN UNIVERSITY AT AUBURN · PI PIAZZA, GARY A · 2021 to 2025
$1.9M
Development of personalized ex vivo predictive technology for rapidly matching patient tumors with chemotherapy regimens before treatment.R43CA254493 · NCI · CERFLUX, INC. · PI BUDHWANI, KARIM I · 2020 to 2021
$301k
Innovate Alabama IA-CerFluxNCI NIH HHS 1R43CA254493-01NCI NIH HHS R01 CA238514NCI NIH HHS R01 CA254197NCI NIH HHS R43 CA254493U.S. National Science Foundation TI-2321805
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

3D bioprintingcolorectal cancerdrug discoveryex vivo tumor modelsnew approach methodspan-RAS inhibitorsRAS mutations

Identifiers

PMID41008802
PMCPMC12468595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.